Rapid Nutrition Chosen to Collaborate with USA University in Landmark Osteoarthritis Prevention Study
- Extensive clinical study spanning two continents, University researchers will determine whether the most common treatments for osteoarthritis – weight loss and exercise – also help prevent women from developing the degenerative joint disease.
- $17.1 million in funding received from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Arthritis Foundation, and the Centers for Disease Control and Prevention, among others.
London, United Kingdom – 20 February 2024 - Rapid Nutrition PLC (Euronext Growth: ALRPD): Rapid Nutrition, a global leader in premium nutrition products, proudly announces its selection as a key partner in the ground-breaking Osteoarthritis Prevention Study (TOPS) led by Wake Forest University. This significant collaboration highlights Rapid Nutrition's commitment to advancing scientific research and promoting women's health on a global scale.
TOPS, spearheaded by Wake Forest University's Department of Health and Exercise Science, has received $17.1 million in funding from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, the Arthritis Foundation, and the Centers for Disease Control and Prevention. This comprehensive five-year initiative marks the first large-scale investigation into the potential preventive effects of weight loss and exercise against osteoarthritis in women.
Rapid Nutrition's participation in TOPS underscores its pivotal role in supporting innovative research initiatives aimed at improving public health outcomes. As a renowned provider of premium nutrition products, Rapid Nutrition's inclusion in the study highlights its dedication to advancing scientific knowledge and driving positive change in the field of women's health.
Simon St Ledger, CEO of Rapid Nutrition, expressed his enthusiasm for the collaboration, stating, "We are honoured to be selected as a key partner in the TOPS study led by Wake Forest University. This collaboration underscores Rapid Nutrition's commitment to promoting women's health and well-being through innovative research and premium nutrition solutions."
The TOPS study will enrol 1,230 women aged 50 and above, who exhibit risk factors for osteoarthritis such as overweight status.
Rapid Nutrition's support of the TOPS study exemplifies its dedication to advancing scientific research and driving positive health outcomes for individuals worldwide. By collaborating with leading academic institutions like Wake Forest University, Rapid Nutrition continues to leverage its expertise to address pressing public health challenges and empower individuals to lead healthier, more fulfilling lives.
For more information about Rapid Nutrition PLC and its product offerings, including market insights, please visit www.rnplc.com.
A
bout Rapid Nutrition
Rapid Nutrition is a leading health and wellness company committed to providing innovative solutions for a healthier world. With a focus on research-backed formulas, we empower individuals to optimize their well-being and face life's challenges with confidence.
Investor Relations Contact:
Disclaimer
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).